Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan and Amlodipine Versus Monocomponent Tablets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Healthy, non-smoking, male and/or post-menopausal/surgically sterile female subjects from 18 to 55 years of age.~2. Females who participate in this study must either:~   1. be post-menopausal for at least 1 year (no menstrual cycle for 12 consecutive months) and deemed post-menopausal by a physician based on screening clinical laboratory tests (Follicle stimulating hormone (FSH) and Luteinising Hormone (LH)~  2. provide proof of surgical sterility.~3. Body Mass Index (BMI) greater than or equal to 19.0 and less than or equal to 30.0 kg/m2.~4. No clinically significant findings in vital signs measurements and systolic blood pressure greater than or equal to 110 mmHg at screening.~5. No clinically significant abnormal laboratory values.~6. No clinically significant findings in a 12-lead electrocardiogram (ECG) and the time between the P and the R waves on the ECG (PR interval) less than or equal to 200 ms at screening.~7. Have no significant diseases.~8. Be informed of the nature of the study and give written consent prior to receiving any study procedure.~9. Have no clinically significant findings from a physical examination.~Exclusion criteria:~1. Known history or presence of any clinically significant medical condition.~2. Known or suspected carcinoma.~3. History or presence of cardiovascular dysfunction (e.g. increased angina, myocardial infarction, outflow obstruction, congestive heart failure).~4. History of clinically significant hypotension.~5. Presence of hepatic dysfunction.~6. Known history or presence of galactose or fructose intolerance, sucrase-isomaltase insufficiency, Lapp lactase insufficiency, galactosemia, or glucose-galactose malabsorption syndrome.~7. History of gastrointestinal tract surgery (appendectomy is permitted).~8. Presence of clinically significant gastrointestinal disease or history of malabsorption within the last year.~9. Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption.~10. History of drug or alcohol addiction requiring treatment.~11. Positive test result for serum hCG consistent with pregnancy (females only), HIV, Hepatitis B surface antigen, or Hepatitis C antibody.~12. Positive test result for urine drugs of abuse (cannabinoids, opiates, amphetamines, cocaine, phencyclidine, tricyclic antidepressants, barbiturates, methadone, and benzodiazepines) or urine cotinine.~13. Difficulty fasting or consuming standard meals.~14. Females who are pregnant, lactating, or likely to become pregnant during the study.~15. Does not tolerate venipuncture.~16. Use of tobacco or nicotine-containing products within 6 months prior to drug administration.~17. On a special diet within 30 days prior to drug administration (e.g. liquid, protein, raw food diet).~18. Participated in another clinical trial or received an investigational product within 30 days prior to drug administration.~19. Donation or loss of whole blood:~    1. Great than or equal to 50 mL and less than or equal to 499 mL within 30 days prior to dosing~   2. greater than or equal to 500 mL within 56 days prior to dosing.~20. Females who have used hormonal contraceptives within 6 months prior to drug administration.~21. Have had a tattoo or body piercing within 30 days prior to dosing.~22. Known history or presence of hypersensitivity or idiosyncratic reaction to telmisartan, amlodipine, or any other drug substances with similar activity.~23. Use of any drugs known to:~    1. induce (e.g. barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole)~   2. inhibit (e.g. antidepressants (Selective Seratonin Reuptake Inhibitor (SSRI)I), cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) hepatic drug metabolism within 30 days prior to drug administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Telmisartan/Amlodipine Fixed Dose (Type: ACTIVE_COMPARATOR): Telmisartan/Amlodipine medium fixed dose combination tablet once daily.
- Amlodipine Monocomponent (Type: ACTIVE_COMPARATOR): Amlodipine Monocomponent 10mg tablet once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete